TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28916603

Group type: EXPERIMENTAL
Intervention: Elamipretide (0.05 mg/kg per hour intravenous infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 26333337

Group type: EXPERIMENTAL
Intervention: Single oral dose of monovalent influenza A H1N1 vaccine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23940221

Group type: EXPERIMENTAL
Intervention: iAMP21 (intrachromosomal amplification of chromosome 21)
Number of subjects: 7793

Group type: EXPERIMENTAL
Intervention: Day 29 MRD ≥ 0.01% and iAMP21
Number of subjects: 7793

Group type: EXPERIMENTAL
Intervention: Absence of both iAMP21 and MRD
Number of subjects: 7793

Group type: COMPARATOR
Intervention: iAMP21
Number of subjects: 7793
Study: 20490632

Group type: EXPERIMENTAL
Intervention: Twelve-step facilitated (TSF) group treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Node-link mapping-enhanced cognitive-behavioral group therapy (CBGT-mapping)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-List control
Number of subjects: 49
Study: 18805240

Group type: EXPERIMENTAL
Intervention: MUS patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mild simulators
Number of subjects: 43

Group type: COMPARATOR
Intervention: Strong simulators
Number of subjects: 43
Study: 16579490

Group type: EXPERIMENTAL
Intervention: fast‐acting WDRC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: slow‐acting AVC
Number of subjects: 50

Group type: COMPARATOR
Intervention: nonlinear fittings
Number of subjects: 50

Group type: COMPARATOR
Intervention: linear reference fittings
Number of subjects: 50
Study: 14552398

Group type: EXPERIMENTAL
Intervention: Training sessions with various analogous tasks; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive-capture strategy; specific details on dosage and duration not available.
Number of subjects: 0
Study: 10944130

Group type: EXPERIMENTAL
Intervention: IFNalpha2a plus 13‐CRA
Number of subjects: 284

Group type: COMPARATOR
Intervention: IFNalpha2a alone
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFNalpha2a plus 13‐CRA)
Number of subjects: 284
Study: 8823826

Group type: EXPERIMENTAL
Intervention: Steroid-eluting electrodes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-steroid electrodes
Number of subjects: 20
Study: 1485705

Group type: EXPERIMENTAL
Intervention: Solcoderm topical application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual conservative treatment
Number of subjects: 50
Study: 3922732

Group type: EXPERIMENTAL
Intervention: Amiodarone (7.5 mg/kg intravenously over 5 minutes followed by oral administration for 3 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (0.8 mg sublingually)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metoprolol (0.15 mg/kg intravenously)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nifedipine (5 ng/kg/min)
Number of subjects: 19
Study: 31384906

Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG water laser treatment
Number of subjects: 272

Group type: COMPARATOR
Intervention: Calcium hydroxide paste (control group)
Number of subjects: 272
Study: 29379043

Group type: EXPERIMENTAL
Intervention: Recall-antigen stimulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mitogen stimulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low arterial oxygen tension (PaO2)
Number of subjects: 76
Study: 27113429

Group type: EXPERIMENTAL
Intervention: MAL‐PDT
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 601
Study: 25262525

Group type: EXPERIMENTAL
Intervention: Isometric exercises group
Number of subjects: 68

Group type: COMPARATOR
Intervention: General exercises group
Number of subjects: 68
Study: 22445107

Group type: EXPERIMENTAL
Intervention: Steroid-antiviral combination therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Steroid-only treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ZSH with pain
Number of subjects: 45
Study: 20436102

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: More abrasive dentifrice
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Less abrasive dentifrice
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Erosion
Number of subjects: 8
Study: 18676418

Group type: EXPERIMENTAL
Intervention: Video-assisted instruction
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 37
Study: 16424846

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia followed by 2‐minute blood warm reperfusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia with no reperfusion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inotropic support
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: No inotropic support
Number of subjects: 70
Study: 12162473

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 200 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 400 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional ibuprofen 200 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional ibuprofen 400 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional ibuprofen
Number of subjects: 500
Study: 10682464

Group type: EXPERIMENTAL
Intervention: Materna treatment (1 tablet daily) in preventive group (n = 96)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Materna treatment (1 tablet daily) in treatment group (n = 93)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (no supplementation) in preventive group (n = 95)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (0.3 g tid/d) in treatment group (n = 50)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Ferroids (1 tablet/d) in treatment group (n = 35)
Number of subjects: 369
Study: 7648860

Group type: COMPARATOR
Intervention: 0% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7% CO2
Number of subjects: 0
Study: 2930094

Group type: EXPERIMENTAL
Intervention: Quit for Life program training (3 hours)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patients of trained internists
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patients of trained internists who wanted to quit
Number of subjects: 81
Study: 683275

Group type: EXPERIMENTAL
Intervention: Somatostatin (2 mg per day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Replacement of glucagon
Number of subjects: 4
Study: 31346968

Group type: EXPERIMENTAL
Intervention: weighted genetic risk score (wGRS) based on four APOE-independent SNPs
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: combined model with wGRS and APOE E4 genotypes
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: cGRS based on seven SNPs
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: wGRS based on seven SNPs
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: cGRS based on four APOE-independent SNPs
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: wGRS based on four APOE-independent SNPs
Number of subjects: 1259
Study: 29425226

Group type: EXPERIMENTAL
Intervention: Pamphlets and one poster on influenza vaccine in GPs' waiting rooms (intervention group)
Number of subjects: 10597

Group type: COMPARATOR
Intervention: Standard waiting rooms without additional advertising (control group)
Number of subjects: 10597
Study: 26258655

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg kg⁻¹ i.v. 30 minutes before surgery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 105
Study: 25011949

Group type: EXPERIMENTAL
Intervention: 3.1 mg otelixizumab administered over 8 days
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 3.1 mg otelixizumab
Number of subjects: 281
Study: 21722284

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 156
Study: 20926152

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 38570

Group type: EXPERIMENTAL
Intervention: COPD without asthmatic symptoms
Number of subjects: 38570
Study: 17989535

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled designs
Number of subjects: 0
Study: 15891593

Group type: EXPERIMENTAL
Intervention: Single-injection gated SPECT with 99mTc tetrofosmin performed 3 days after primary PCI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single-injection gated SPECT with 99mTc tetrofosmin
Number of subjects: 45
Study: 12486510

Group type: EXPERIMENTAL
Intervention: Fixed combination of 0.005% latanoprost and 0.5% timolol once daily in the morning
Number of subjects: 436

Group type: COMPARATOR
Intervention: Latanoprost once daily in the morning
Number of subjects: 436

Group type: COMPARATOR
Intervention: Timolol twice daily
Number of subjects: 436
Study: 9293599

Group type: EXPERIMENTAL
Intervention: 2 hiking sticks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 hiking stick
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 hiking sticks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 hiking sticks with load
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 hiking sticks with load
Number of subjects: 15
Study: 8048625

Group type: EXPERIMENTAL
Intervention: Multiparameter deconvolution analysis
Number of subjects: 0
Study: 2979244

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (2 g b.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 20
Study: 29889762

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bilateral tubal ligation
Number of subjects: 80
Study: 28094136

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual pump therapy
Number of subjects: 31
Study: 26351349

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 or 3 mg/kg, intravenous infusion every 2 weeks)
Number of subjects: 20
Study: 24271253

Group type: EXPERIMENTAL
Intervention: Bed-exit alarm system
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 98
Study: 20951491

Group type: EXPERIMENTAL
Intervention: Gastric aspiration
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 310
Study: 18465331

Group type: EXPERIMENTAL
Intervention: Simple mastectomy with postoperative radiotherapy
Number of subjects: 425

Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Clinical stage I tumours
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Grade I tumours
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Premenopausal patients
Number of subjects: 425

Group type: COMPARATOR
Intervention: Postmenopausal patients
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 425
Study: 16472041

Group type: EXPERIMENTAL
Intervention: IMB-based HIV risk-avoidance intervention
Number of subjects: 557

Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 557
Study: 14527113

Group type: EXPERIMENTAL
Intervention: Wrist extension orthosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free hand
Number of subjects: 0
Study: 11185669

Group type: EXPERIMENTAL
Intervention: Cholestyramine (12 g/d) in addition to chronic statin therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (statin therapy only)
Number of subjects: 25
Study: 9365450

Group type: EXPERIMENTAL
Intervention: Oral morphine 1.9 mg/kg every 12 h plus intravenous placebo (saline)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous morphine 0.04 mg/kg/h plus placebo tablet
Number of subjects: 56
Study: 7917912

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 fragments intravenously at doses of 1, 3 and 5 micrograms kg‐1 body weight during s.c. IL‐2 treatment.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at MTD of 5 micrograms kg‐1.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms kg‐1.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at 5 micrograms kg‐1.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 treatment.
Number of subjects: 12
Study: 2844088

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 29510762

Group type: EXPERIMENTAL
Intervention: Healthy Body Image programme (intervention group)
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Control condition (control group)
Number of subjects: 2481
Study: 28252882

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) combined with Treatment as Usual (TAU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 80
Study: 25494333

Group type: EXPERIMENTAL
Intervention: Tai Chi training (6-month duration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tai Chi experts (no intervention)
Number of subjects: 60
Study: 23217149

Group type: EXPERIMENTAL
Intervention: Orthopaedists - Range of Motion (ROM)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Orthopaedists - Muscle Strength
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chiropractors - Range of Motion (ROM)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chiropractors - Muscle Strength
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall assessment of clinical hip OA
Number of subjects: 109
Study: 21166550

Group type: EXPERIMENTAL
Intervention: GPS-based transportation device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (map and verbal directions)
Number of subjects: 0
Study: 17393260

Group type: EXPERIMENTAL
Intervention: 500 mg acetylic salicylic acid
Number of subjects: 16
Study: 15691900

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (49.5 g essential amino acids and 90 g carbohydrate per day for 28 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 13
Study: 12384201

Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 79

Group type: COMPARATOR
Intervention: NGM/EE
Number of subjects: 79
Study: 9564116

Group type: EXPERIMENTAL
Intervention: Health-care workers' evaluation using the Therapy Impact Questionnaire (TIQ)
Number of subjects: 159
Study: 8015776

Group type: EXPERIMENTAL
Intervention: Laser-aided drainage using an angulated endolaser probe set at 1 W for 0.2 seconds, average of 2.4 laser burns
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transchoroidal needle drainage
Number of subjects: 50
Study: 2513741

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.015 mg/kg IV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29731406

Group type: EXPERIMENTAL
Intervention: Health Promoting Conversations intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 29231605

Group type: EXPERIMENTAL
Intervention: qi‐conducting needling technique at the governor vessel acupoints combined with electroacupuncture (EA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional electroacupuncture (EA)
Number of subjects: 201
Study: 24285491

Group type: EXPERIMENTAL
Intervention: Early metacarpal bone mineral density (BMD) loss after 4 months of treatment
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Presence of baseline erosions
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early metacarpal BMD loss in patients without baseline erosions
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Radiological progression after 1 year
Number of subjects: 610
Study: 23645236

Group type: EXPERIMENTAL
Intervention: Ziprasidone (137.5 mg/d)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Olanzapine (19.5 mg/d)
Number of subjects: 260
Study: 21915616

Group type: EXPERIMENTAL
Intervention: Higher serum total cholesterol (≥240 mg/dl)
Number of subjects: 29093

Group type: EXPERIMENTAL
Intervention: Higher HDL cholesterol
Number of subjects: 29093
Study: 18355139

Group type: EXPERIMENTAL
Intervention: Ho:YAG laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: LithoClast 2
Number of subjects: 50
Study: 16832617

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neomycin (in methane producers)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (in methane producers)
Number of subjects: 39
Study: 12605618

Group type: EXPERIMENTAL
Intervention: Rapid infusion (RI) of 150 mg thiamine over 1 hour
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow infusion (SI) of 150 mg thiamine over 24 hours
Number of subjects: 12
Study: 10848859

Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 91
Study: 9356537

Group type: EXPERIMENTAL
Intervention: Fish oil treatment (20 g fish oil/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fish oil treatment with increased fiber intake (15 g pectin supplement)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fish oil treatment with increased fiber intake
Number of subjects: 15
Study: 1607194

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 5 days (treated partners)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (untreated partners)
Number of subjects: 54
Study: 3896609

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conservative treatment (Group II)
Number of subjects: 90
Study: 30983049

Group type: EXPERIMENTAL
Intervention: AF ablation with point‐by‐point radiofrequency energy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AF ablation with cryoballoon technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edoxaban for periprocedural oral anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging integration with cardiac magnetic resonance or computed tomography
Number of subjects: 0
Study: 30204689

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 254

Group type: COMPARATOR
Intervention: Vaginal progesterone (200 mg/24 hours)
Number of subjects: 254
Study: 27435280

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery
Number of subjects: 438

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) followed by surgery
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CROSS protocol)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (FLOT protocol)
Number of subjects: 438
Study: 25118116

Group type: EXPERIMENTAL
Intervention: High pulse pressure (>40 mm Hg)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Low pulse pressure (≤40 mm Hg)
Number of subjects: 754
Study: 22371836

Group type: EXPERIMENTAL
Intervention: Clips (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Silicone resilient liners (group II)
Number of subjects: 30
Study: 20534147

Group type: EXPERIMENTAL
Intervention: Exercise group (18-week supervised group exercise programme)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (maintain habitual physical activity pattern)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 300
Study: 18577410

Group type: EXPERIMENTAL
Intervention: Diphtheria CRM(197)‐based Haemophilus influenzae type b conjugate vaccine (HbOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphtheria CRM(197)‐based combination 9‐valent pneumococcal conjugate vaccine/meningococcal group C conjugate vaccine
Number of subjects: 0
Study: 16238663

Group type: EXPERIMENTAL
Intervention: Teacher-mediated intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12454841

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Repeated paracentesis plus intravenous albumin
Number of subjects: 70
Study: 10321658

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, maximum 800 mg, administered intravenously over 30 to 60 mins every 6 hrs for eight doses)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo (glycine buffer vehicle)
Number of subjects: 455
Study: 8755119

Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells with mucosal invasion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells with submucosal invasion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF expression and tumor progression
Number of subjects: 101
Study: 1722793

Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg/day for 6 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 7042699

Group type: EXPERIMENTAL
Intervention: Amitriptyline, 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenelzine, 60 mg/day
Number of subjects: 0
Study: 30865730

Group type: EXPERIMENTAL
Intervention: Active Case Finding (ACF)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Passive Case Finding (PCF)
Number of subjects: 465